Savings & Support

Learn about SpringWorks CareConnections™, a program that offers support and resources just for people taking OGSIVEO.

SpringWorks CareConnections™ is a free, personalized patient support program to help you navigate your insurance coverage and answer questions about your treatment.

If you have been prescribed OGSIVEO, ask your doctor to help you enroll in the SpringWorks CareConnections Patient Support Program, so you can have access to support, or click here to get started.

Enroll Now
SpringWorks CareConnections™ logo

Insurance Navigation and Financial Help*

The SpringWorks CareConnections Nurse Advocates can offer information about financial assistance options, as well as information that explains your insurance coverage

SpringWorks CareConnections™ COPAY card

Commercially insured patients may pay as little as a $0 copay for each OGSIVEO prescription through the Commercial Copay Program*

Enroll Now
SpringWorks CareConnections™ logo

Additional support may be available through SpringWorks CareConnections to help you save
on OGSIVEO

Call 844-CARES-55 (844-227-3755)
Monday – Friday 8 AM – 10 PM ET for more information

Visit SpringWorks CareConnections

*Terms and conditions apply. Copay program is subject to an annual benefit maximum. Full terms and conditions provided during enrollment process and are available upon request by contacting SpringWorks CareConnections at 844-CARES-55 (844-227-3755).

A SpringWorks CareConnections™ Nurse Advocate taking a support call

Personalized Educational and Emotional Support for Patients

The SpringWorks CareConnections team of dedicated Nurse Advocates can provide you with ongoing, personalized support no matter where you are in your treatment journey with OGSIVEO.

If you have started taking OGSIVEO, you can count on support from your Nurse Advocate to help keep you on track with your treatment.†

The SpringWorks CareConnections Patient Support Program is not intended to take the place of your healthcare provider, and the team of Nurse Advocates cannot provide medical or clinical advice.

NEXT PAGE

Patient Resources
What is Ogsiveo?
Important Safety Information

What is OGSIVEO?  

OGSIVEO is a prescription medication used to treat adults with progressing desmoid tumors who require a medicine by mouth or injection (systemic therapy). It is not known if OGSIVEO is safe and effective in children.

Important Safety Information  

Before taking OGSIVEO tell your healthcare provider about all of your medical conditions, including if you:

  • Have liver problems.
  • Are pregnant or plan to become pregnant. OGSIVEO can harm your unborn baby. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment.
  • Females who are able to become pregnant:
    • Your healthcare provider will give you a pregnancy test before you start treatment with OGSIVEO.
    • You should use effective birth control during treatment and for 1 week after the last dose. Talk to your healthcare provider about methods that may be right for you.
    • Stop taking OGSIVEO and tell your healthcare provider right away if you become pregnant.
  • Males with female partners who are able to become pregnant should use effective birth control during treatment with OGSIVEO and for 1 week after the last dose.
  • Are breastfeeding or plan to breastfeed. It is not known if OGSIVEO passes into your breast milk. Do not breastfeed during treatment with OGSIVEO and for 1 week after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You should avoid taking proton pump inhibitors (PPIs) and H2 blockers during treatment with OGSIVEO. Ask your healthcare provider if you are not sure if you take one of these medicines. 

How should I take OGSIVEO? 

  • Take OGSIVEO exactly as your healthcare provider tells you to take it.
  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with OGSIVEO if you develop side effects.
  • Take OGSIVEO 2 times a day with or without food.
  • Swallow OGSIVEO tablets whole. Do not break, crush, or chew.
  • If you take an antacid medicine, take OGSIVEO 2 hours before or 2 hours after the antacid.
  • If you vomit after taking a dose or miss a dose of OGSIVEO, take your next dose at your regular time. Do not take 2 doses of OGSIVEO to make up the dose.

What should I avoid while taking OGSIVEO? 

Avoid eating or drinking grapefruit products, Seville oranges, and starfruit during treatment with OGSIVEO.  

What are the possible side effects of OGSIVEO? 

OGSIVEO can cause serious side effects, including:

  • Diarrhea. Diarrhea is common with OGSIVEO and may sometimes be severe. Your healthcare provider may tell you to drink more fluids or to take antidiarrheal medicines. Tell your healthcare provider right away if you have diarrhea that lasts longer than a few days and does not get better after taking antidiarrheal medicines.
  • Ovarian problems. Females who are able to become pregnant may have ovarian problems and changes in their menstrual cycle during treatment. OGSIVEO may affect fertility which may affect your ability to have a child. Tell your healthcare provider if you have any changes in your menstrual cycle or hot flashes, night sweats, or vaginal dryness during treatment.
  • Liver problems. OGSIVEO can increase liver enzymes. Your healthcare provider will do blood tests to check your liver function before you start and during treatment with OGSIVEO.
  • New non-melanoma skin cancers. Your healthcare provider will do skin exams before and during treatment with OGSIVEO if you are at risk for skin cancer. Tell your healthcare provider if you have any new or changing skin lesions.
  • Electrolyte (salt) problems. Your healthcare provider will do blood tests to check your phosphate and potassium levels during treatment and may give you medicines to treat low phosphate or low potassium if needed. Tell your healthcare provider if you develop any muscle pain or weakness.

Tell your healthcare provider right away if you have any side effect that bothers you or that does not go away. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with OGSIVEO.  

The most common side effects of OGSIVEO are: 

  • rash 
  • nausea 
  • tiredness 
  • mouth sores 
  • headache 
  • stomach (abdominal) pain 
  • cough 
  • hair loss 
  • upper respiratory infection 
  • shortness of breath 

OGSIVEO can affect fertility in females and males, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you.
These are not all of the possible side effects of OGSIVEO. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see full Prescribing Information and Patient Information for OGSIVEO.

What is OGSIVEO?  

OGSIVEO is a prescription medication used to treat adults with progressing desmoid tumors who require a medicine by mouth or injection (systemic therapy). It is not known if OGSIVEO is safe and effective in children.

Please see full Prescribing Information and Patient Information for OGSIVEO.

close
Discover moreDiscover more

References
  1. Cancer.Net. Desmoid tumor: introduction. Accessed October 16, 2023. //www.cancer.net/cancer-types/desmoid-tumor/introduction
  2. NIH. National Cancer Institute Center for Cancer Research. Desmoid tumor. Accessed October 16, 2023. //www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-soft-tissue-tumors/desmoid-tumor
  3. Kasper B, Baumgarten C, Garcia J, et al. Desmoid Working Group. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28(10):2399-2408.
  4. Orphanet Report Series: Rare Diseases Collection. Prevalence and incidence of rare diseases: bibliographic data. Number 1, January 2022. Accessed October 16, 2023. //www.orpha.net/orphacom/cahiers/docs/GB/ Prevalence_of_rare_diseases_by_alphabetical_list.pdf.
  5. van Broekhoven DLM, Grünhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817-2823.
  6. U.S. Department of Commerce. News Blog. U.S. population estimated at 332,403,650 on Jan. 1, 2022. Accessed October 16, 2023. //www.commerce.gov/news/blog/2022/01/us-population-estimated-332403650-jan-1-2022
  7. Penel N, Coindre JM, Bonvalot S, et al. Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France. Eur J Cancer. 2016;58:90-96.
  8. Skubitz KM. Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc. 2017;92(6):947-964.
  9. Easter DW, Halasz NA. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann Surg. 1989;210(6):765-769.
  10. Gurbuz AK, Giardiello FM, Petersen GM, et al. Desmoid tumours in familial adenomatous polyposis. Gut. 1994;35(3):377-381.
  11. Constantinidou A, Scurr M, Judson I, Litchman C. Clinical presentation of desmoid tumors. In: Litchman C, ed. Desmoid Tumors. Springer; 2012:chap 2. Accessed October 16, 2023. //www.researchgate.net/publication/226455135
  12. Shinagare AB, Ramaiya NH, Jagannathan JP, et al. A to Z of desmoid tumors. AJR Am J Roentgenol. 2011;197(6):W1008-W1014.
  13. Tchangai BK, Tchaou M, Alassani F, et al. Giant abdominopelvic desmoid tumour herniated trough perineum: a case report. J Surg Case Rep. 2021;2021(8):rjab295. doi:10.1093/jscr/rjab295.
  14. McDonald ES, Yi ES, Wenger DE. Best cases from the AFIP: extraabdominal desmoid-type fibromatosis. Radiographics. 2008;28(3):901-906.
  15. Scaramussa FS, Castro UB. Desmoid tumor in hand: a case report. SM J Orthop. 2016;2(3):1036.
  16. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 16, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  17. Gronchi A, et al. Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients [supplementary appendix]. Eur J Cancer. 2020;127:96-107.
  18. Cancer.Net. Desmoid tumor: diagnosis. Accessed October 16, 2023. //www.cancer.net/cancer-types/desmoid-tumor/diagnosis
  19. Huss S, Nehles J, Binot E, Wardelmann E, et al. b-Catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology. 2013;62:294-304. DOI: 10.1111/j.1365-2559.2012.04355.
  20. Referenced with permission from the NCCN Guidelines for Patients® for Soft Tissue Sarcoma, V.1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed October 16, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way.
  21. Cancer.Net. The oncology team. Accessed October 16, 2023. //www.cancer.net/navigating-cancer-care/cancer-basics/cancer-care-team/oncology-team
  22. Singhi E, Feldman J, West H. The multidisciplinary cancer conference. JAMA Oncology. December 2022
  23. NIH. National Library of Medicine. Medline plus: Abdominal exploration-series-normal anatomy. Accessed October 16, 2023. //medlineplus.gov/ency/presentations/100049_1.htm
  24. NIH. National Cancer Institute. NCI dictionary of cancer terms: benign. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/benign
  25. NIH. National Cancer Institute. NCI dictionary of cancer terms: connective tissue. Accessed October 16, 2023. //www.cancer.gov/search/results?swKeyword=connective+tissue
  26. NIH. National Cancer Institute. NCI dictionary of cancer terms: colectomy. Accessed October 16, 2023. //www.cancer.gov/search/results?swKeyword=colectomy
  27. NIH. National Cancer Institute. NCI dictionary of cancer terms: CT scan. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/ct-scan
  28. NIH. National Library of Medicine. Medline plus: Electrolytes. Accessed October 16, 2023. //medlineplus.gov/ency/article/002350.htm#:~:text=Electrolytes%20are%20minerals%20in%20your,Your%20muscle%20function
  29. Shrimanker I, Bhattarai S. Electrolytes. [Updated 2022 Jul 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Accessed October 16, 2023. //www.ncbi.nlm.nih.gov/books/NBK541123/
  30. NIH. National Cancer Institute. NCI dictionary of cancer terms: FAP. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/fap
  31. NIH. National Cancer Institute. NCI dictionary of cancer terms: Fibromatosis. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/fibromatosis
  32. NIH. National Cancer Institute. NCI dictionary of cancer terms: GIST. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/gist
  33. Rabello FB, Souza CD, Farina JA. Update on hypertrophic scar treatment. Clinics. 2014;69(8):565-573. DOI: 10.6061/clinics/2014(08)11
  34. NIH. National Cancer Institute. NCI dictionary of cancer terms: leiomyoma. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/leiomyoma
  35. NIH. National Cancer Institute. NCI dictionary of cancer terms: lipoma. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/lipoma
  36. NIH. National Library of Medicine. Medline plus: Phosphate in blood. Accessed October 16, 2023. //medlineplus.gov/lab-tests/phosphate-in-blood/
  37. NIH. National Cancer Institute. NCI dictionary of cancer terms: malignant. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/malignant
  38. NIH. National Cancer Institute. NCI dictionary of cancer terms: medical oncologist. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/medical-oncologist
  39. NIH. National Cancer Institute. NCI dictionary of cancer terms: metastasize. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/metastasize
  40. NIH. National Cancer Institute. NCI dictionary of cancer terms: MRI. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/mri
  41. Allison DB, Wakely Jr PE, Siddiqui MT, Ali SZ. Nodular fasciitis: A frequent diagnostic pitfall on fine-needle aspiration. Cancer Cytopathology. 2017;125(1):20-29.
  42. NIH. National Cancer Institute. NCI dictionary of cancer terms: pathologist. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/pathologist
  43. National Cancer Institute. NCI dictionary of cancer terms: radiation oncologist. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/radiation-oncologist
  44. NIH. National Cancer Institute. NCI dictionary of cancer terms: radiologist. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/radiologist
  45. NIH. National Cancer Institute. NCI dictionary of cancer terms: sarcoma. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/sarcoma
  46. NIH. National Cancer Institute. NCI dictionary of cancer terms: surgical oncologist. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/surgical-oncologist
  47. NIH. National Cancer Institute. NCI dictionary of cancer terms: schwannoma. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/schwannoma
  48. NIH. National Cancer Institute. What are rare soft tissue tumors? Accessed October 16, 2023. //www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-soft-tissue-tumors
  49. NIH. National Cancer Institute. NCI dictionary of cancer terms: ultrasound. Accessed October 16, 2023. //www.cancer.gov/publications/dictionaries/cancer-terms/def/ultrasound